Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

II clinical trial designed to evaluate the safety and efficacy of ispinesib in the treatment of patients with chemotherapy-na? recurrent or metastatic malignant melanoma was recently completed. In Stage 1 of this two-stage clinical trial, 17 patients received ispinesib as monotherapy at 18 mg/m2 as a 1-hour intravenous infusion every 21 days. The trial s primary endpoint was objective response as determined using the RECIST criteria. This trial was designed to require at least 1 confirmed partial response in 15 patients in Stage 1 in order to proceed to Stage 2. The best overall response was stable disease seen in 6 of 17 patients treated. In this clinical trial, ispinesib did not satisfy the criteria for advancement to the second stage and therefore recruitment to Stage 2 was not opened. The toxicity profile was consistent with other previously reported Phase II clinical trials of ispinesib. A manuscript is being prepared.

A Phase II clinical trial designed to evaluate the safety and efficacy of ispinesib for the treatment of hormone refractory prostate cancer who had failed taxane-based chemotherapy was recently completed. In Stage 1 of this two-stage clinical trial, 21 patients received ispinesib as monotherapy at 18 mg/m2 as a 1-hour intravenous infusion every 21 days. The trial s primary endpoint was objective response as determined using the RECIST criteria and a prostate-specific antigen (PSA) response of a greater than 50% decline confirmed 3 weeks later. This trial was designed to require a minimum of 1 PSA response in the first 20 evaluable patients in Stage 1 in order to proceed to Stage 2. No patient met the criteria for a PSA response and the median time to PSA or clinical progression was 9 weeks. In this clinical trial, ispinesib did not satisfy the criteria for advancement to the next stage in the clinical trial. The toxicity profile was consistent with other previously reported Phase II clinical trials of ispinesib. A manuscrip
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:4/1/2015)... Salix Pharmaceuticals, Ltd. (the " Company " ... Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) (TSX:VRX), ... Fundamental Changes, Make-Whole Fundamental Changes and Merger Event, Fundamental ... and Offer to Purchase (the " Notice ") to ... (the " Notes "), pursuant to the Indenture, dated ...
(Date:4/1/2015)... -- New York College of Health Professions announces a valuable ... U.S. Patent #8,996,098 donated by its Chairman under the ... instrument that allows surgeons to view and compare what ... traditional format of a slide that is used during ... thus providing the surgeon real time analysis and information. ...
(Date:4/1/2015)... , April 1, 2015  Hologic, Inc. (NASDAQ: ... holders of the 2.00% Convertible Exchange Senior Notes due ... and Wilmington Trust Company, the trustee, paying agent and ... to convert the notes.  This conversion right is subject ... notes dated as of December 10, 2007, as supplemented ...
Breaking Medicine Technology:Salix Provides Notice of Fundamental Changes, Make-Whole Fundamental Changes and Merger Event Relating to Its 1.5% Convertible Senior Notes Due 2019 2Salix Provides Notice of Fundamental Changes, Make-Whole Fundamental Changes and Merger Event Relating to Its 1.5% Convertible Senior Notes Due 2019 3Salix Provides Notice of Fundamental Changes, Make-Whole Fundamental Changes and Merger Event Relating to Its 1.5% Convertible Senior Notes Due 2019 4Salix Provides Notice of Fundamental Changes, Make-Whole Fundamental Changes and Merger Event Relating to Its 1.5% Convertible Senior Notes Due 2019 5Salix Provides Notice of Fundamental Changes, Make-Whole Fundamental Changes and Merger Event Relating to Its 1.5% Convertible Senior Notes Due 2019 6Salix Provides Notice of Fundamental Changes, Make-Whole Fundamental Changes and Merger Event Relating to Its 1.5% Convertible Senior Notes Due 2019 7Ground-Breaking Surgical Instrument Allows Surgeons to obtain Real Time Biopsies 2Ground-Breaking Surgical Instrument Allows Surgeons to obtain Real Time Biopsies 3Hologic Delivers Notice that Holders of 2.00% Convertible Exchange Senior Notes Due 2037 are Eligible to Convert 2
... Feb. 19, 2011 Genoptix, Inc. (Nasdaq: ... a memorandum of understanding ("MOU") providing for the settlement ... the Superior Court of the State of California, San ... Genoptix, Inc., Case No. 37-2011-00050762-CU-BT-NC, (2) Schwitters v. Genoptix, ...
... 18, 2011 TLC Vision announced today its plans for ... in San Diego.  Internationally recognized as leaders in field of ... Tanzer MD will lend their surgical skill and expertise to ... center will continue to be at the forefront of working ...
Cached Medicine Technology:Genoptix Enters Into Memorandum of Understanding Related to Class Action Lawsuits 2Genoptix Enters Into Memorandum of Understanding Related to Class Action Lawsuits 3Genoptix Enters Into Memorandum of Understanding Related to Class Action Lawsuits 4Genoptix Enters Into Memorandum of Understanding Related to Class Action Lawsuits 5Genoptix Enters Into Memorandum of Understanding Related to Class Action Lawsuits 6Genoptix Enters Into Memorandum of Understanding Related to Class Action Lawsuits 7Genoptix Enters Into Memorandum of Understanding Related to Class Action Lawsuits 8Genoptix Enters Into Memorandum of Understanding Related to Class Action Lawsuits 9Genoptix Enters Into Memorandum of Understanding Related to Class Action Lawsuits 10Genoptix Enters Into Memorandum of Understanding Related to Class Action Lawsuits 11TLC Vision Announces TLC Laser Eye Center San Diego 2
(Date:4/2/2015)... Atlanta-based Kanga, the first SaaS-based platform for management ... Up in Atlanta by General Assembly Atlanta. Six companies ... LOV, Ticket Alternative, and TripTap. T General Assembly presented ... 500 at their Atlanta Launch Party at Ponce City ... platform for initiating, managing and tracking last mile deliveries ...
(Date:4/1/2015)... In April, the Science Museum of Virginia will ... by illuminating Richmond’s historic train station with blue lights. ... of businesses, schools and organizations who will ‘go blue’ ... up the night sky – and the future of ... the 8th annual awareness campaign spearheaded by Autism Speaks, ...
(Date:4/1/2015)... One year ago today, the USO cut the ribbon on ... States and changed the landscape on Naval Support Activity Bethesda ... more than 100,000 troops and military families in the last ... injured and their families, proving to be a valuable resource ... the country. After opening its doors on the campus that ...
(Date:4/1/2015)... After a particularly harsh winter, many roads are ... to costly damage, so Amica Insurance has tips ... following suggestions from AAA: , , Inspect ... to the manufacturer’s recommended levels. , ... uneven tire wear can be signs of bad shocks or ...
(Date:4/1/2015)... April 01, 2015 It all began at ... Di Gasbarro, who was on a mission to create a ... simple ingredients that parents could trust. Now, Shoosha Truly Organic ... Organic skincare products, meaning all products contain a minimum 95% ... , Babies’ skin is considered to be 40% thinner than ...
Breaking Medicine News(10 mins):Health News:Kanga Wins Best Start Up in Atlanta 2Health News:USO’s Warrior and Family Center at Bethesda Marks First Anniversary and More than 100,000 Servicemen and Women Served 2Health News:USO’s Warrior and Family Center at Bethesda Marks First Anniversary and More than 100,000 Servicemen and Women Served 3Health News:USO’s Warrior and Family Center at Bethesda Marks First Anniversary and More than 100,000 Servicemen and Women Served 4Health News:USO’s Warrior and Family Center at Bethesda Marks First Anniversary and More than 100,000 Servicemen and Women Served 5Health News:Prepare for potholes with 7 tips from Amica Insurance 2Health News:Just in Time for Earth Day This April, Shoosha Truly Organic’s Skincare Line Soothes and Protects Mom and Baby’s Sensitive Skin with Pure, Simple and Organic Ingredients 2Health News:Just in Time for Earth Day This April, Shoosha Truly Organic’s Skincare Line Soothes and Protects Mom and Baby’s Sensitive Skin with Pure, Simple and Organic Ingredients 3
... offers immediate health research and solutions for consumers and ... site. , ... Denver, CO (Vocus) December 16, 2008 ... of the timeliest, informative and content-rich web sites devoted to the ...
... Partners Medical Group, a top-rated multispecialty medical group in Southern California, ... Huntington Drive, Suite 101, in Monrovia. , ... Torrance, ... top-rated coordinated-care medical group in Southern California, announced the opening of ...
... 16 Cell Therapeutics, Inc.(CTI),(Nasdaq and MTA: CTIC) ... Pharmaceuticals, Inc. to form a 50/50 owned joint ... Zevalin(R) ([90Y]-ibritumomab,tiuxetan) in the United States. In ... payment of $7.5 million and will receive an,additional ...
... (SACRAMENTO, Calif.) -- A secondary analysis of a large, ... with fruits, vegetables and fiber and somewhat lower in ... risk of recurrence in a subgroup of early-stage breast ... by approximately 31 percent. These patients typically have ...
... 15 Dechra Veterinary Products,LLC today announces that ... Capsules. , ... been demonstrated,to be effective in the treatment of ... use in pituitary-dependent hyperadrenocorticism, which,comprises the majority of ...
... 15 ProAssurance,Corporation (NYSE: PRA ) ... for an undisclosed price. Mid-Continent is a Managing ... a year in premiums from,ancillary healthcare providers and ... 2008, Mid-Continent has underwritten,approximately $1.5 million of premium ...
Cached Medicine News:Health News:FeelGoodNow.com Launches Complementary and Preventative Web Site 2Health News:HealthCare Partners Opens a New Medical Office in Monrovia, CA 2Health News:Cell Therapeutics and Spectrum Pharmaceuticals Close Transaction Forming Joint Venture to Market Zevalin in the US 2Health News:Cell Therapeutics and Spectrum Pharmaceuticals Close Transaction Forming Joint Venture to Market Zevalin in the US 3Health News:Cell Therapeutics and Spectrum Pharmaceuticals Close Transaction Forming Joint Venture to Market Zevalin in the US 4Health News:Cell Therapeutics and Spectrum Pharmaceuticals Close Transaction Forming Joint Venture to Market Zevalin in the US 5Health News:Diet may cut risk of breast cancer recurrence in women without hot flashes 2Health News:Diet may cut risk of breast cancer recurrence in women without hot flashes 3Health News:ProAssurance Acquires Mid-Continent General Agency to Expand Ancillary Healthcare Insurance Business 2Health News:ProAssurance Acquires Mid-Continent General Agency to Expand Ancillary Healthcare Insurance Business 3Health News:ProAssurance Acquires Mid-Continent General Agency to Expand Ancillary Healthcare Insurance Business 4Health News:ProAssurance Acquires Mid-Continent General Agency to Expand Ancillary Healthcare Insurance Business 5